GSK and Flagship Pioneering to Invest $150M in Innovative Health Solutions
GSK and Flagship Pioneering to Invest $150M in Innovative Health Solutions
GSK plc (NYSE:GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
GSK plc（纽交所：GSK）和创始先锋（Flagship）生物平台创新公司今天宣布，他们已经开展合作，旨在发现和开发未来改变医药和疫苗组合的产品组合，始于呼吸和免疫领域。
This alliance brings together GSK's disease area expertise and development capability with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.
本次联合合作集合了GSK的疾病领域专业知识和开发能力，以及Flagship的生物平台公司、创新模式和技术，旨在推进医疗卫生领域的重大创新。
GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship's bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to $720 million in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme.
GSK和Flagship将初期预先资助15000万美元，以支持勘探阶段，以便确定最有前景进行进一步研究和开发的前沿科学概念。根据协议条款，双方将面向获得的每个项目分别签署专属期权，以进行进一步的临床开发。Flagship及其生物平台公司有资格从GSK获得高达72000万美元的预先资金、开发和商业里程碑款项，以及获得每个已收购项目的临床前资金和阶梯式版税。
